CK-19对乳腺癌新辅助化疗疗效的评估价值

目的探讨细胞角蛋白19（cytokeratin19，CK-19）检测对乳腺癌患者新辅助化疗疗效评估的价值。方法采用实时定量逆转录聚合酶链反应（qRT—PCR）技术检测114例乳腺癌患者新辅助化疗前后外周血CK-19mRNA表达水平的变化。结果化疗前乳腺癌患者的CK-19mRNA阳性率为36．8％（42／114），与患者的年龄、肿瘤大小，TNM分期、绝经状态、雌激素受体（ER）及孕激素受体（PR）的表达无关（P〉0．05），而与腋窝淋巴结转移及临床分期有关（P〈0．01）。化疗后CK-19mRNA表达水平较化疗前明显降低（P〈0．01）。结论CK-19可以作为乳腺癌患者新辅助化疗疗效的评价指标之一。

The value of CK - 19 for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer

Objective To explore the value of cytokeratin 19 （CK- 19） for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer. Methods The CK - 19 mRNA expression in the blood of 114 breast cancer patients was detected before and after neoadjuvant chemotherapy by real - time quantitative RT - PCR （ qRT - PCR）. Results The positive rate of C K - 19 mRNA in breast cancer patients before treatment was 36.8% （42/114）, and the patient＇s age, tumor size, TNM staging, menopausal status, the expression of estrogen receptor （ER）, and progesterone receptor （PR） were not associated with the expression level of CK - 19 mRNA, but the expression level of CK - 19 mRNA showed strong correlation with axillary lymph node metastasis and clinical stage. After chemotherapy, the expression level of CK - 19 mRNA was significanly lower than that before chemotherapy. Conclusion CK - 19 can be used as one of the early indi- cators of efficacy in neoadjuvant chemotherapy for breast cancer patients.